# Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis

> **NCT00213538** · — · COMPLETED · sponsor: **University Hospital, Rouen** · enrollment: 341 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Response to anakinra associated with methotrexate

## Key facts

- **NCT ID:** NCT00213538
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00213538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00213538, "Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00213538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*